Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Test entities : Castle biosciences, inc. save search
New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
Published: 2023-10-18 (Crawled : 23:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.88%
H: 1.02%
C: -3.2%
conference test
Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: -2.43%
tissuecypher test results
TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus
Published: 2023-09-14 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.54%
H: 0.89%
C: -5.43%
tissuecypher test care
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
Published: 2023-08-07 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
tissuecypher management test publication
Framework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational Dermatology
Published: 2023-06-05 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -22.13%
H: 0.96%
C: -34.12%
decisiondx test cell results
Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation
Published: 2023-05-15 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 0.35%
H: 3.12%
C: 2.66%
tissuecypher award test innovation
TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia
Published: 2023-04-20 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.98%
H: 3.64%
C: 2.96%
tissuecypher management test results
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
Published: 2022-10-31 (Crawled : 17:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.85%
H: 13.95%
C: 9.86%
decisiondx care test impact cancer study cell carcinoma
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
Published: 2022-10-25 (Crawled : 13:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 1.82%
H: 7.87%
C: 5.65%
tissuecypher care management test results
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: -6.83%
decisiondx risk management test impact one results cell carcinoma
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
Published: 2022-10-20 (Crawled : 23:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.23%
H: 4.71%
C: -0.41%
decisiondx test results perform study
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline
Published: 2022-10-13 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -5.49%
H: 5.93%
C: 4.56%
tissuecypher risk test trial results
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -4.31%
H: 11.41%
C: 10.61%
conference test skin cancer
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
Published: 2022-06-14 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -1.36%
H: 0.0%
C: -6.32%
decisiondx melanoma research test
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
Published: 2022-05-27 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 5.47%
H: 7.62%
C: 7.39%
decisiondx test awards
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
Published: 2022-05-06 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -7.1%
H: 0.42%
C: -2.31%
america genetic depression test
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
Published: 2022-04-29 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 1.34%
H: 3.61%
C: -1.63%
contract cancer test
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
Published: 2022-04-27 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -3.01%
H: 3.96%
C: 0.66%
tissuecypher risk test cancer
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
Published: 2022-04-18 (Crawled : 12:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -10.41%
H: 0.0%
C: -5.98%
conference disease test dermatitis skin
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
Published: 2022-03-29 (Crawled : 22:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: 2.03%
H: 6.86%
C: 5.77%
tissuecypher diagnostic services test
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.